InvestorsHub Logo
Followers 1
Posts 59
Boards Moderated 0
Alias Born 08/19/2021

Re: None

Tuesday, 09/21/2021 3:12:03 PM

Tuesday, September 21, 2021 3:12:03 PM

Post# of 5322
Dr Tauber has definitely had successful contact with the FDA in the past. I wonder if he can use any leverage behind the scenes for Immunopass even though his expertise is in dry eye and the like. I’m probably crazy but in business there are often strategic advantages that would never appear in an announcement or press release but are very important.

Speculation - I know nothing about how the FDA works and/or the EUA process works.

“He has served as a Principal Investigator in over 140 multicenter clinical trials including those that led to the approval of all four medications currently approved by the FDA for the treatment of dry eye – Restasis, Xiidra, Cequa and Eyesuvis.”


https://www.globenewswire.com/news-release/2021/09/21/2300614/0/en/AXIM-Biotechnologies-Appoints-Joseph-Tauber-MD-Chief-Medical-Officer-and-Chairman-of-its-Medical-Advisory-Board.html
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AXIM News